Dupilumab (Dupixent) for Moderate to Severe Atopic Dermatitis

Date: April 24, 2017 Issue #:  1519Summary:  The FDA has approved dupilumab (Dupixent– Sanofi/Regeneron), a subcutaneously-injected fully human monoclonal antibody, for treatment of adults with moderate to severe atopic dermatitis (eczema) that has not responded to topical therapies. It can be used with or without topical corticosteroids.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: Antibacterials Atopic dermatitis corticosteroids crisaborole Cyclosporine dupilumab Dupixent Elidel Eucrisa Phototherapy Pimecrolimus Protopic Tacrolimus Source Type: research